



Charles River Laboratories Extends Global Alliance with Rules-Based Medicine, Inc.

November 4, 2005

WILMINGTON, MA, November 4, 2005 – The Research Models and Services division of Charles River Laboratories International, Inc. (NYSE:CRL) (Charles River) and Rules-Based Medicine, Inc. (RBM) today announced the collaborated extension and expansion of their exclusive worldwide agreement. Under this contract, Charles River Laboratories will market RBM's proprietary Multi-Analyte Profiles (MAPs) for the phenotypic characterization of laboratory research models through evaluation of alterations in biomarker patterns.

RBM provides MAPs with the goal of cost-effective detection and understanding of the early signs of disease or therapeutic intervention revealed by blood biomarkers associated with cancer, infectious disease, autoimmunity and cardiovascular risk, as well as cytokines/chemokines, acute-phase reactants and other blood components. Today, RBM's MAPs are used for discovery of biomarker patterns in mice, rats, guinea pigs, hamsters, and humans. Sample types include plasma, serum, cerebrospinal fluid, bronchoalveolar lavage, cell culture supernatant, tissue extract and other fluids.

William Barbo, Charles River Laboratories Corporate Vice President, North American Research Model Services, said, "Charles River is delighted to be expanding our relationship with RBM. The value of biomarker analysis as a tool in drug discovery and development is very exciting. Charles River's leadership role in Laboratory Animal and Preclinical Services, along with RBM's expertise in biomarker detection and interpretation are a natural fit, adding value for our clients."

Craig Benson, President and CEO of Rules-Based Medicine added, "RBM is extremely pleased to strengthen our collaboration with a market leader like Charles River Laboratories. We look forward to the continued delivery of quality data and services in support of the biomarker initiatives of our clients."

About Charles River Laboratories

Charles River Laboratories, based in Wilmington, Massachusetts, U.S., is a global provider of solutions that advance the drug discovery and development process. Our leading-edge products and services are designed to enable our clients to bring drugs to market faster and more efficiently. Backed by our rigorous, best-in-class procedures and our proven data collection, analysis and reporting capabilities, our products and services are organized into three categories spanning every step of the drug development pipeline: Research Models and Services, Preclinical Services, and Clinical Services. Charles River's customer base includes all of the major pharmaceutical companies and many biotechnology companies, government agencies and leading hospitals and academic institutions. Charles River's 8,000 employees serve clients in more than 50 countries. For more information on Charles River, visit our website at www.criver.com.

About Rules-Based Medicine, Inc.

Rules-Based Medicine ("RBM"), an Austin, Texas based biotechnology company, develops and markets proprietary products and services to the pharmaceutical, biotechnology, diagnostic and medical research industries. RBM provides, as a service, a comprehensive, quantitative screening approach that identifies patterns of protein biomarkers associated with various disease states or therapeutic treatments. This unique cost-effective approach provides a better understanding of disease and its treatment leading to more efficient drug development and novel diagnostics. For more information on Rules-Based Medicine, Inc., visit www.rulesbasedmedicine.com or call 1-866 RBM-MAPS.

Contact:

Elizabeth Ferber
Director, Global Communications
T: 978-658-6000 ext. 1693
F: 978-658-7841
corpcomm@crl.com